Health Policy Podcast
The 340B drug pricing program
The 340B drug pricing program was created to help hospitals and clinics serve vulnerable patients, but guests on the Health Policy Podcast argue it often fails to get those discounts to patients and has grown far beyond its original scale.
The show has covered 340B in four episodes: a Sept. 10, 2026, interview with Sydney Halleman, senior editor at Healthcare Dive, on proposed payment cuts from the Centers for Medicare and Medicaid Services and the fight over hospital funding, rural facilities, site-neutral payments and price transparency; an April 14 interview with Peter Mihalick, advocacy director at the International Hearing Society, on loose regulations, a lack of transparency, and savings that are not passed through to patients; a Jan. 21 interview with Ross Marchand, executive director of the Taxpayers Protection Alliance, on how 340B has increased costs for taxpayers and patients when hospitals do not pass on savings; and an interview with Wayne Winegarden, a fellow at the Pacific Research Institute, on the program's lack of transparency, large hospital systems profiting at the expense of smaller institutions and patients, and the program's growth from under $1 billion to more than $80 billion in discounted purchases.
Podcast interviews
Untangling 340B: Medicare's Proposed Payment Cuts and the Future of Healthcare
Sydney Halleman
Proposed 340B payment cuts from the Centers for Medicare and Medicaid Services would hit hospitals, especially rural facilities, and feed a larger fight over site-neutral payments and price transparency, says Sydney Halleman, senior editor at Healthcare Dive, in a Health Policy Podcast interview with Bryan Hyde. The discussion covers the implications of these cuts on hospitals, particularly rural facilities, and the ongoing debate surrounding site-neutral payments and price transparency in healthcare. The episode provides insights into the challenges of healthcare policy reform and the lobbying efforts from various stakeholders.
Peter Mihalick Explains the Challenges of the 340B Drug Pricing Program
Pete Mihalik
The 340B program, designed to provide discounted outpatient drugs to eligible facilities, often fails to benefit patients directly because of loose regulations and a lack of transparency, says Peter Mihalick, advocacy director at the International Hearing Society. Mihalick highlights how the program, designed to provide outpatient drugs at discounted rates to eligible facilities, often fails to benefit patients directly due to loose regulations and the lack of transparency in the system. He emphasizes the need for reforms to ensure that the savings from the program are passed on to patients in need.
340B drug pricing: Ross Marchand on hospital discounts that leave patients and taxpayers with higher costs
Ross Marchand
The 340B drug pricing program was meant to provide discounted drugs to hospitals, but it has increased costs for taxpayers and patients when hospitals do not pass on the savings, says Ross Marchand, executive director of the Taxpayers Protection Alliance. He highlights how the program, intended to provide discounted drugs to hospitals, has led to increased costs for taxpayers and patients as hospitals often do not pass on savings. Marchand advocates for reducing government involvement in healthcare to improve cost and quality.
Pacific Research Institute's Wayne Winegarden on 340B Drug Pricing Program's 'Lack of Transparency'
Wayne Winegarden
The 340B Drug Pricing Program lacks transparency and has had unintended consequences that let large hospital systems profit at the expense of smaller institutions and patients, says Wayne Winegarden of the Pacific Research Institute. Winegarden critiques the program's lack of transparency and its unintended consequences, which have led to large hospital systems profiting at the expense of smaller institutions and patients. He advocates for reforms, including improved transparency and a shift in funding models to better serve the intended vulnerable populations.
Key quotes
“Critics have really accused this program of basically funneling money to hospitals without that money actually getting to patients.”
“The Trump administration is proposing to cut the amount of money that they send through this program by about a third.”
“The real issue is though, is that none of the directives from Congress in establishing the program force the hospitals or clinics to actually provide anything for those particular patients.”
“What has actually been happening with the 340B program is it's being abused.”
“340B is the most important drug program that you've never heard of.”
“The program has gone from, you know, less than a billion dollars back then, maybe $7 billion in 2012. Now it's more than $80 billion kind of purchases kind of at the discounted price.”




